title: Twelve-month clinical outcomes after coronary stenting with the Genous Bio-engineered R Stent in patients with a bifurcation lesion:  from the e-HEALING (Healthy Endothelial Accelerated Lining Inhibits Neointimal Growth) registry.
abstract: BACKGROUND
  The e-Healthy Endothelial Accelerated Lining Inhibits Neointimal Growth (e-HEALING) registry was designed to capture clinical data on the use of the endothelial progenitor cell capture stent (ECS) in routine clinical practice. In this analysis, we investigated the 12-month clinical outcomes in patients treated with an ECS for a bifurcation lesion.
  
  
  METHODS
  The worldwide, prospective, nonrandomized e-HEALING registry aimed to enroll 5000 patients treated for coronary artery disease with one or more ECS between October 2005 and October 2007. Clinical follow-up was obtained at 1, 6, and 12 months. The primary endpoint was target vessel failure (TVF), defined as the composite of cardiac death, myocardial infarction, and target vessel revascularization at 12 months.
  
  
  RESULTS
  A total of 573 patients were treated for at least one bifurcation lesion and were assessed in the current analysis. Baseline characteristics showed a median age of 65 years; 21% were diabetic patients and 36% had unstable angina. A total of 63% of the bifurcation lesions were located in the left artery descending and the mean stent length was 20.7±12.6 mm. At 12 months, TVF was 12.7% and target lesion revascularization was 7.5%. Definite or probable stent thrombosis occurred in 1.7% of the patients. Moreover, one or more stents per lesion [hazard ratio (HR): 2.79, 95% confidence interval (CI): 1.60-4.86, P<0.001], predilatation (HR: 0.39, 95% CI: 0.17-0.87, P=0.023), and lesions located in the right coronary artery (HR: 4.56, 95% CI: 1.07-19.5, P=0.041) were independent predictors of TVF.
  
  
  CONCLUSIONS
  In the e-HEALING registry, coronary bifurcation stenting with the ECS results in favorable clinical outcomes and low incidences of repeat revascularization and stent thrombosis.
authors.affiliation: Department of Cardiology, University of Amsterdam, Amsterdam, the Netherlands.
authors.forename: Marcel A
authors.initials: MA
authors.lastname: Beijk
authors.forename: Peter
authors.initials: P
authors.lastname: Damman
authors.forename: Margo
authors.initials: M
authors.lastname: Klomp
authors.forename: Pier
authors.initials: P
authors.lastname: Woudstra
authors.forename: Sigmund
authors.initials: S
authors.lastname: Silber
authors.forename: Manfred
authors.initials: M
authors.lastname: Grisold
authors.forename: Expedito E
authors.initials: EE
authors.lastname: Ribeiro
authors.forename: Harry
authors.initials: H
authors.lastname: Suryapranata
authors.forename: Jaroslaw
authors.initials: J
authors.lastname: Wójcik
authors.forename: Kui Hian
authors.initials: KH
authors.lastname: Sim
authors.forename: Jan G P
authors.initials: JG
authors.lastname: Tijssen
authors.forename: And Robbert J
authors.initials: AR
authors.lastname: de Winter
mesh_terms: D000368:Aged; D015906:Angioplasty, Balloon, Coronary; D057005:Bioengineering; D003324:Coronary Artery Disease / Q000401:mortality / Q000628:therapy*; D054855:Drug-Eluting Stents; D004730:Endothelium, Vascular / Q000166:cytology; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D015994:Incidence; D008297:Male; D008875:Middle Aged; D009204:Myocardial Revascularization / Q000379:methods*; D011358:Product Surveillance, Postmarketing; D011446:Prospective Studies; D012042:Registries; D013234:Stem Cells; D013927:Thrombosis / Q000209:etiology; D016896:Treatment Outcome